Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kyorin Pharma PI4KB compound 30
- Development stage
- Unknown
- Lead developer
- Kyorin Pharmaceutical
01
Overview
Kyorin Pharma PI4KB compound 30: sourced facts only. name: "Furthermore, compound 30 selectively inhibited PI4KB, with minimal off-target kinase activity, as confirmed by profiling." [PMID:40701196]; target: "Furthermore, compound 30 selectively inhibited PI4KB, with minimal off-target kinase activity, as confirmed by profiling." [PMID:40701196]; developer: "Watarase Research Center, Kyorin Pharmaceutical Co., Ltd., 1848 Nogi, Nogi-machi, Shimotsuga-gun, Tochigi 329-0114, Japan." [PMID:40701196]
02
Targets
PI4KB (Phosphatidylinositol 4-kinase beta)
Beyond the preview
Go deeper on Kyorin Pharma PI4KB compound 30.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kyorin Pharma PI4KB compound 30.